The current digital era is marked by a complex array of technologies and novel ones being developed at an astonishing pace.
Regardless of the source reviewed, there are some technologies that are consistently high-ranked and considered to have high disruptive potential of the current healthcare industry such as AI, Genomics, Precision Medicine, Robotics, Nanotechnology, Blockchain/DLT to only name a few. The full portfolio of technological tools that are influencing healthcare delivery on a daily basis is certainly richer and encompasses Telehealth, Wearables/Sensors, Machine Vision, 3D Printing, Exoskeletons, Brain-Computer Interfaces, Internet of Bodies etc.
When evaluating each one of these, it is important to consider multiple complex factors such as their scalability, cost, safety, and more importantly their impact on population health.
From a cost perspective, some are clearly on the higher end of a cost curve (such as Brain-Computer Interfaces) and will likely require several more years before they can be deployed at a larger scale globally.
From a safety perspective, they all have to undergo rigorous approval by the FDA before they can transition from an innovation- or research domain to becoming standard of care.
However, Genomics and Precision Medicine seem to stand out as having a tremendous potential for optimizing population health. The reason for their transformative potential is largely due to the latest truly exponential pace of scientific discoveries within both of these domains, a significant reduction in cost over the past decade and their amenability to scale relatively quickly to larger population segments.
Using the tremendous capabilities within the AI repertoire such as predictive algorithms, machine learning or neural networks can certainly expedite this process further and act as a catalyst for improving outcomes, as well as facilitate the development of novel precision medicine solutions.
The combined deployment of AI & DLT could also enhance the scalability of these novel solutions and could have a profound transformative impact on global population health.
In order for this type of strategy to be successful, it would require breaking down existing silos within the global healthcare ecosystem, reinventing the way R&D is being designed within the life sciences industry and having an exponential medicine visionary approach.
So what are the characteristics of a completely redesigned exponential medicine AI & DLT-powered global healthcare ecosystem?
The defining element would be enhanced access for patients to precision medicine solutions for patients world-wide. Another key feature would be to maximize the benefits of DLT which would allow all stakeholders to act in synergy in order to facilitate the development of these novel precision medicine solutions. Last, but not least, it would be essential to wisely and ethically deploy genomics-based precision medicine in order to shift from a "sick-care" healthcare delivery system to a "preventative health" and "well-care" system.
Ingrid Vasiliu-Feltes, MD MBA Is a healthcare executive, futurist and globalist who is highly dedicated to digital and ethics advocacy. She is a Forbes Business Council member, digital strategist, passionate educator and entrepreneurship ecosystem builder, known as an expert speaker, board advisor and consultant. Throughout her career she has received several awards for excellence in research, teaching or leadership. She is the recipient of numerous awards most notably: WBAF World Excellence AwardSocial Entrepreneurship 2021, Top 20 Global Leaders in Digital Twins Technologies, Top 50 Global Leaders in Health Tech,Top 50 Global Ecosystem Leaders, Top 100 Visionary In Education Award 2021, Top 100 Global Women in Leadership Award 2021, Top 100 World Women Vision Award, 2021-Innovation & Tech, Top 100 Women in Social Enterprise 2021 (nominee),Top 50 Global Thinkers (Nominee),Nations of Women Change Makers Award(finalist),Top 100 Healthcare Leader 2020 Award, Top 100 Finance Leader 2020 Award, and Top 100 Women in Crypto 2020. Additionally, she serves as an Expert Advisor to the EU Blockchain Observatory Forum, and was appointed to the Board of UN Legal and Economic Empowerment Network. Dr. Vasiliu-Feltes is CEO of Softhread Inc., the Founder and CEO of The Science, Entrepreneurship and Investments Institute, and currently serving as a Country Director for WBAF USA, Senator of WBAF, Faculty Member of the WBAF Business School-Division of Entrepreneurship, and teaching the Executive MBA Business Technology Course at the UM Business School. She is also acting as the Chief Innovation Officer for the Government Blockchain Association. Most recently she served as President of Detect Genomix, Chief Quality and Safety Officer Chief and Innovation Officer for Mednax, Chief Quality and Safety Officer and Chief of Compliance for the University of Miami UHealth System During her academic tenure she taught several courses within the Medical School, as well as the combined MD/PhD and MD/MPH programs. Throughout her career, Dr. Vasiliu-Feltes held several leadership positions and is a member of numerous prestigious professional organizations. She holds several certifications, such as Bioethics from Harvard, Artificial Intelligence and Business Strategy from MIT Sloan, Blockchain Technology and Business Innovation from MIT Sloan, Finance from Harvard Business School, Negotiation from Harvard Law School, Innovation and Entrepreneurship from Stanford Graduate School of Business, Certified Professional in Healthcare Risk Management, Fellow of the American College of Healthcare Executives, Patient Safety Officer by the International Board Federation of Safety Managers, Master Black Belt in Lean and Six Sigma Management, Professional in Healthcare Quality by the National Association of Healthcare Quality, Manager for Quality and Organizational Excellence, by the American Society for Quality, and Certified Risk Management Professional by the American Society for Healthcare Risk Management. Additionally, Dr. Vasiliu-Feltes is an Honorary Advisory Board Member of several companies, as well as an Editorial Board Member for several international publications, an author and TV/Media partner.